Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03270241 · ClinicalTrials.gov registry record · NA

Early Molecular Changes in Vitiligo After Narrowband Ultraviolet Therapy

A NA study of Vitiligo and Dermatology/Skin - Other, sponsored by Johns Hopkins University.

Completed
Registry status
NA
Development phase
10
Enrollment target
1
Study location

NCT03270241: Completed NA study of Vitiligo and Dermatology/Skin - Other, sponsored by Johns Hopkins University.

NCT03270241 is a NA study of Vitiligo and Dermatology/Skin - Other that has completed, run by Johns Hopkins University. The registered enrollment target is 10 participants, below the 1,124-participant average among 15 other Vitiligo trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03270241, a NA study of Vitiligo and Dermatology/Skin - Other, has completed, sponsored by Johns Hopkins University.

COMPLETED
Registry status
NA
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

Vitiligo is a chronic acquired cutaneous disease of pigmentation that affects patients' quality of life across all degrees of involvement and severity. Phototherapy, such as Narrow band UVB (NB-UVB), is a clinically indicated treatment for skin lesions. NB-UVB treatment has been shown to promote repigmentation and normalize cellular behaviors. The investigators would like to analyze the change in protein expression and histological change in skin from NB-UVB treatment in participants with Vitiligo. The investigators are recruiting participants with Vitiligo on the body, arms, and/or legs.

Primary Outcome

The investigators are assessing the histological and molecular changes of normal and Vitiligo-lesion skin from NB-UVB therapy. The molecular markers (in microgram/ mL) include, but not limited to, KIT receptor, stem cell factor (SCF), tumor necrosis factor-alpha (TNF-alpha), and interleukin-1 (IL-1).

Interventions

  • DEVICE Phototherapy (NB-UVB) via the 3 Series PC & SP phototherapy cabinet

Study Locations (1)

Maryland

  • Johns Hopkins Outpatient Center - Baltimore

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2017-10-01
Est. Completion 2023-03-14
Phase NA
Johns Hopkins University

1,448 total trials

What the finished NCT03270241 record still lists

NCT03270241 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 1,124-participant average among 15 other Vitiligo trials with a reported enrollment target (99% lower).

The record links to 2 conditions, with Vitiligo appearing as the primary indexed condition, and to 1 intervention - of which Phototherapy (NB-UVB) via the 3 Series PC & SP phototherapy cabinet is the first listed.

NCT03270241 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT03270241 about?

NCT03270241 is a clinical study titled "Early Molecular Changes in Vitiligo After Narrowband Ultraviolet Therapy". Vitiligo is a chronic acquired cutaneous disease of pigmentation that affects patients' quality of life across all degrees of involvement and severity. Phototherapy, such as Narrow band UVB (NB-UVB), is a clinically indicated treatment for skin lesions. NB-UVB treatment has been shown to promote rep...

What is the current status of trial NCT03270241?

This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2017-10-01. Estimated completion is 2023-03-14.

What conditions does trial NCT03270241 study?

This clinical trial studies the following conditions: Vitiligo, Dermatology/Skin - Other.

What interventions are being tested in trial NCT03270241?

The interventions under investigation include: Phototherapy (NB-UVB) via the 3 Series PC & SP phototherapy cabinet (DEVICE).

Who is sponsoring clinical trial NCT03270241?

This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03270241 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Vitiligo

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03270241's enrollment target sits among peer trials

10 15th of 15 higher than 1 of 15 other Vitiligo trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Vitiligo trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00623389 · 10 participants · NA

    Evaluation of an Advanced Lower Extremity Neuroprostheses

  • NCT01241864 · 10 participants · Phase 2

    Islet Transplantation in Type 1 Diabetic Kidney Allograft

  • NCT01293214 · 10 participants · NA

    Vascularized Composite Allotransplantation for Multiple Extremity Amputations

  • NCT01474148 · 10 participants · NA

    A Neuroprosthesis for Seated Posture and Balance

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03270241, the US trial registry maintained by the National Library of Medicine. NCT03270241 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.